METHODS AND MATERIALS
 This was a prospective observational cohort study.
 We identified patients for a month trial of CSDPI who were clinically intolerant of or demonstrated poor adherence to nebulised colistimethate sodium (NCS).
 At test dose of CSDPI, the following were recorded: -Demographics -Spirometry -Reason for switching to CSDPI  At 1 month review, the following were documented: -Spirometry -Side effects  Patients were asked to compare the following parameters with regards to use of NCS and CSDPI: -Ease of use -Time taken to perform one dose (including preparation, administration and care of nebuliser equipment or inhaler device) -Satisfaction -Estimated adherence  Patients were also asked to rate their: -Likelihood of continuing with CSDPI -Treatment preference CONCLUSIONS  Despite reporting significant difficulties with the Colobreathe ® , all patients who tolerated a full month of Colobreathe ® expressed a preference for this rather than nebulised colistimethate sodium and planned to continue long-term.
 Early real world evidence suggests that Colobreathe ® is well tolerated, easier to use, less inconvenient and associated with improved adherence compared to nebulised colistimethate sodium.
 Longer-term outcomes are needed to assess whether these benefits are maintained and are associated with improved clinical outcomes.
RESULTS (continued)
Other outcomes  CSDPI was reported to be easier to use than NCS and less time consuming.  All patients who tolerated a full month of CSDPI, expressed a preference for this rather than NCS and planned to continue long-term, despite some initial reports of device functioning issues.
Data in the following tables reflects patients who had used NCS for at least 1 month consistently in the preceding 12 months and who were continuing with CSDPI at 1 month review.
Preparation and administration

Satisfaction
Patient comments regarding Colobreathe ®  "It"s a very good product . I can"t believe how much of a difference it has made to me in terms of convenience and time."  "It"s easy to use. I can take it in my handbag and use it on the move."  "It saves time and it"s easier to organise within my treatment plan. I"m excited about when the manufacturers get the inhaler design right."  "I tolerated Promixin ® better but the ease of doing Colobreathe ® outweighs the chest tightness I get with it."  "I"ve sometimes breathed in bits of capsule and I"m concerned that they might be going onto my lungs."  "I"m very disappointed with the design of the device and the way the capsules fracture. When this happens there can be a large influx of powder all at once which causes coughing -I then feel I"m losing the powder that I"ve breathed in."  "I"m worried that I may not always be getting a full dose. Sometimes when the capsules crack, powder is left in the inhaler or it gets stuck behind the pieces of broken capsule and I have to try and shake/open the capsule to free the trapped powder."  "Powder starts to build up on the inside of the inhaler. This stops the capsules from spinning properly and sometimes I get a "gush" of powder and sometimes very little. A supply of two inhalers rather than one a month would be better."  "Sometimes bits of the capsule get stuck in the inhaler and I have to use a pencil to get them out." 
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RESULTS
 23 patients (10 male) with median age 31 yrs and FEV 1 58.5% predicted were recruited.
 10 patients trialled CSDPI due to intolerance of NCS (INTOL group) and 13 patients due to poor adherence to NCS (ADH group).
Lung function  Combining both groups, FEV 1 did not change from baseline to 1 month visits in patients who completed a full month of CSDPI. FEV 1 pre-test dose of CSDPI was 59% predicted (IQR 42-85%) and at 1 month review was also 59% predicted (IQR 43-81%) (p=0.04).
Tolerance  At 1 month review: -7/10 patients in the INTOL group and 12/13 patients in the ADH group successfully tolerated a full month of CSDPI and planned to continue. -4/23 patients discontinued CSDPI before or at 1 month review due to the intolerable side effects of bronchospasm (4/4) and cough (1/4). -Of the 19 patients continuing with CSDPI, 7/19 reported tolerable side effects of cough (5/7), bronchospasm (1/7), sore throat (1/7). Adherence  At 1 month review: -In the ADH group, reported adherence was higher with CSDPI (median 100% of doses) compared with NCS (50% of doses) (p=0.002).
